DGX · XBRL financial data

Quest Diagnostics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DGX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	9,437	10,788	9,883	9,252	9,872	11,035
Cost of revenue	5,804	6,579	6,450	6,199	6,628	7,370
Gross profit	3,633	—	—	—	—	—
Selling, general and administrative	1,550	1,727	1,874	1,642	1,770	1,967
Other operating income (expense)	(9)	2	(11)	(41)	(1)	12
Operating income (loss)	1,971	2,381	1,428	1,262	1,346	1,556
Interest expense	166	152	148	163	—	—
Other income (expense)	76	369	(55)	20	30	26
Income tax expense (benefit)	460	597	264	248	273	314
Net income (loss)	1,431	1,995	946	854	871	992
Earnings per share, basic USD per share	10.62	15.85	8.10	7.59	7.78	8.87
Earnings per share, diluted USD per share	10.47	15.55	7.97	7.49	7.69	8.75
Weighted average shares, basic millions of shares	134	125	116	112	111	111
Weighted average shares, diluted millions of shares	136	128	118	113	113	113

Fiscal years (DGX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,158	872	315	686	549	420
Accounts receivable	1,520	1,438	1,195	1,210	1,304	1,408
Inventory	223	208	192	190	188	189
Prepaid and other current assets	157	223	196	286	351	361
Total current assets	3,058	2,741	1,898	2,372	2,392	2,378
Property and equipment, net	1,627	1,707	1,766	1,816	2,113	2,203
Right-of-use asset	604	597	585	602	651	657
Goodwill	6,873	7,095	7,220	7,733	8,856	8,945
Total assets	14,026	13,611	12,837	14,022	16,153	16,225
Accrued liabilities	356	460	392	287	306	338
Current portion of long-term debt	2	2	2	303	602	504
Total current liabilities	1,776	1,753	1,551	1,815	2,169	2,278
Long-term debt	4,013	4,010	3,978	4,410	5,615	5,167
Lease liability, non-current	499	494	489	503	535	537
Retained earnings	9,303	7,649	8,290	8,825	9,360	9,994
Total stockholders' equity	6,759	6,444	5,893	6,307	6,778	7,170
Total liabilities and equity	14,026	13,611	12,837	14,022	16,153	16,225
Common shares outstanding (cover page) millions of shares	133	119	111	111	111	110

Fiscal years (DGX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,431	1,995	946	854	871	992
Stock-based compensation	97	79	77	77	88	88
Depreciation and amortization	361	408	437	439	493	570
Net cash from operating activities	2,005	2,233	1,718	1,272	1,334	1,886
Purchases of property and equipment	418	403	404	408	425	527
Net cash from investing activities	(772)	21	(543)	(1,061)	(2,548)	(631)
Share repurchases	325	2,199	1,408	275	151	450
Dividends paid	297	309	305	314	331	353
Net cash from financing activities	(1,267)	(2,540)	(1,732)	160	1,084	(1,388)
Net change in cash	—	(286)	(557)	371	(137)	(129)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Quest Diagnostics	797	3,097	611*	110.0M	—	Q3 FY26 10-QSep 30, 2026
Labcorp Holdings	262	3,810	564*	81.2M	—	Q3 FY26 10-QSep 30, 2026
Natera	1,092	753	55*	144.1M	—	Q2 FY26 10-QJun 30, 2026
Exact Sciences	956	878*	152*	190.9M	—	Q4 FY25 10-KDec 31, 2025
Guardant Health	1,053	335	(58)*	134.2M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.